Physician profile
Eric Michael Bank
NPI 1720423882
$2,802.79
in general payments reported to CMS, 2019-2025
42 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $582 · 2021: $34.21 · 2022: $183 · 2023: $34.98 · 2024: $89.04 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108 · Education: $59.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.79 |
| Education | $59.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $290.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $199.97 | 2019-2020 | |
| Celgene Corporation | $177.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $166.70 | 2020-2022 | |
| Foundation Medicine, INC. | $161.66 | 2019 | |
| Genentech USA, INC. | $155.61 | 2019 | |
| Alexion Pharmaceuticals, INC. | $134.54 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $121.90 | 2019 | |
| Genzyme Corporation | $103.74 | 2019-2020 | |
| Pfizer INC. | $100.28 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $86.75 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $78.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.53 | 2019 | |
| Lilly USA, LLC | $75.34 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Rigel Pharmaceuticals, INC. | $66.32 | 2019 |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.